Introduction
PCSK9 (proprotein convertase subtilisin/kexin Type 9) is a protein, mainly synthesized and secreted by the liver, which binds to specific proteins and escorts them to endosomes/lysosomes compartments for degradation. 1, 2 The low-density lipoprotein receptor (LDLR) has been identified as the main target of PCSK9 3 ; mice lacking Pcsk9 exhibit an increased hepatic LDLR expression, resulting in an increased clearance of circulating low-density lipoprotein (LDL) and hypocholesterolaemia, 4 while PCSK9 overexpression induces a two-fold increase in plasma cholesterol levels. 5 In humans, several mutations in PCSK9 gene were described, with 'gain-of-function' mutations associated to familial hypercholesterolaemia (FH) 6 and 'loss of function' mutations linked to low-LDL-cholesterol (LDL-C) levels. 7, 8 On these premises, anti-PCSK9 therapies have been developed, and monoclonal antibodies against PCSK9 are available for the treatment of patients with severe hypercholesterolaemia and/or very high cardiovascular risk.
While the liver is the main contributor to circulating PCSK9, 9 other tissues produce PCSK9 pointing to a possible role of this protein beyond the control of LDLR expression in the liver. 1, 10 Of note, the LDLR is abundantly expressed by pancreatic b cells in humans, mice, and rats, where it plays a key role in the uptake of plasma LDL. 11, 12 Cholesterol homeostasis is crucial for b cells function and survival; excessive cholesterol accumulation causes a significant reduction in the islets' ability to secrete insulin in response to glucose, 13 and prolonged exposure to high levels of LDL or very low-density lipoprotein could also be lethal for b cells. 12, 14 Increased LDLR expression and cholesterol content were observed in the pancreas of Pcsk9-deficient mice, 15, 16 suggesting also a potential role for the protein in this tissue.
Interestingly, in three different Mendelian randomization studies, the analysis of the effects of genetic scores consisting of independently inherited polymorphisms in the PCSK9 gene resulted into reduced LDL-C levels and cardiovascular events but was also associated with an increased risk of diabetes [17] [18] [19] ; furthermore, patients with FH (decreased LDLR function) appear to have a lower risk of diabetes. 20 On this background, we investigated the molecular mechanisms beyond the impaired glucose metabolism observed in PCSK9-deficient state and tested (i) whether the absence of the LDLR rescues the phenotype by studying Pcsk9/Ldlr double KO (DKO) mice and (ii) the role of circulating/liver-derived PCSK9.
Here, we show that PCSK9 deficiency is associated with impaired glucose tolerance in mice, which appears to be the consequence of decreased insulin secretion from the pancreas rather than insulin resistance. This effect appears to be largely independent from liverderived PCSK9.
Materials and methods
A detailed description of mice, dietary regimens, glucose tolerance and insulin tolerance tests, pancreatic islet staining, western blot analysis, analysis of cholesterol accumulation in pancreatic islets, bioinformatics, and statistical analysis is presented as the Supplementary material online.
Results
Pcsk9 deficiency is associated with impaired glucose tolerance but not with insulin resistance
To evaluate the effect of PCSK9 on plasma glucose, mice were fed with a standard fat diet (SFD) or a high-fat diet (HFD) for 20 weeks. Despite similar plasma glucose levels at baseline, following glucose tolerance test (GTT), the absence of PCSK9 resulted in a significant delay of glucose clearance in both the SFD ( Figure 1A-D) or the HFD ( Figure 1E -H) groups after 12 or 20 weeks of diet. The plasma glucose area under the curve (AUC) in all conditions was significantly higher in Pcsk9 KO mice compared with WT ( Figure 1C , D, G, and H). The observation that Pcsk9 KO mice presented glucose intolerance following GTT in spite of similar baseline glucose levels (following overnight fasting) prompted us to perform a fast and refeeding experiment to better understand possible differences in plasma glucose levels under physiological conditions.
After overnight fasting and ad libitum refeeding (4 h), Pcsk9 KO mice presented a significant increase in plasma glucose levels compared with WT littermates (268 ± 6 mg/dL for Pcsk9 KO compared with 219 ± 30 mg/dL for WT mice, P = 0.008) in spite of similar food consumption (2.27 ± 0.43 g/4 h vs. 2.18 ± 0.38 g/4 h). This observation confirmed the presence of impaired glucose tolerance in Pcsk9 KO mice and set the stage for investigating whether this effect was the consequence of impaired insulin tolerance.
Insulin tolerance test (ITT) was performed in WT and Pcsk9 KO mice, after a 4 h fast. The animals were injected with insulin (0.2 IU/kg body weight) intraperitoneally. The decrease in plasma glucose levels was similar in WT and Pcsk9 KO mice fed with an SFD (Figure 2A and B) or an HFD (see Supplementary material online, Figure S1A and B) for 12 or 20 weeks, thus excluding the presence of insulin resistance in the Pcsk9-deficient state. To further extend this finding, we measured the ratio between phosphorylated Akt vs. total Akt as an index
Translational perspective
Mendelian randomization studies have shown that PCSK9 genetic variants associate with lower low-density lipoprotein cholesterol but higher fasting plasma glucose levels and increased risk of Type 2 diabetes. The investigation of molecular mechanisms responsible for this effect demonstrated that the deficiency of locally but not of circulating proprotein convertase subtilisin/kexin Type 9 (PCSK9) is responsible for increased low-density lipoprotein receptor expression in pancreatic islets, which results in cholesterol accumulation and beta-cell dysfunction. These data suggest that anti-PCSK9 therapies, which target mainly circulating PCSK9, might have a limited impact on beta-cell dysfunction and the incidence of diabetes in contrast to Mendelian randomization analysis, where the effect of global PCSK9 deficiency was investigated. Figure S2A and B) under basal and following IP insulin injection, suggesting that downstream activation of insulin receptor is not affected by Pcsk9 deficiency.
Pcsk9 deficiency results in impaired insulin secretion and histological abnormalities in pancreatic islets
We then investigated whether Pcsk9 deficiency affects insulin production and pancreatic b-cell function. Plasma insulin and C-peptide levels were significantly decreased in Pcsk9 KO mice compared with WT littermates ( Figure 2C ); a similar profile was observed in HFD-fed mice (see Supplementary material online, Figure S1C ). Following fasting and refeeding experiments, a reduced increment in plasma insulin levels in Pcsk9 KO mice was observed vs. WT mice ( Figure 2D) . Similarly, following IP glucose injection, plasma insulin levels increased to a lower extent in Pcsk9 KO mice compared with WT animals (see Supplementary material online, Figure S1D ). We next evaluated whether the phenotype observed in Pcsk9 KO mice could also be the consequence of altered incretins production. GLP1 and GIP plasma levels in fasted and refed conditions were similar in WT and Pcsk9 KO mice ( Figure 2E and F). The same was true when incretin's levels were measured following an oral bolus of glucose (see Supplementary material online, Figure S1E and F). In contrast to decreased circulating levels, we observed that pancreatic insulin content was significantly increased in Pcsk9 KO mice compared with WT mice ( Figure 3A ) (see Supplementary material online, Figure S1G ). These data suggest that Pcsk9 mutant KO mice might have a defective insulin secretion, which could lead to an increased accumulation in beta cells. We, therefore, studied pancreatic islets morphology and observed that islets from Pcsk9 KO mice present with irregular shape ( Figure 3B and Supplementary material online, Figure S3A ). A detailed analysis of consecutive pancreatic sections from three different regions of each pancreas (see Supplementary material online, Figure   S3B ) showed larger islet size ( Figure 3C ) together with a significant increase in the major and minor axis of each islet in the pancreas of Pcsk9 KO mice compared with WT mice ( Figure 3D and E). These findings were paralleled by a different islet size distribution between Pcsk9 KO and WT mice ( Figure 3F) .
To further extend these data in humans, we investigated the impact of the PCSK9 46L variant on the homeostasis model assessment: insulin resistance (HOMA-IR) and beta-cell function (HOMA-BC). HOMA-BC but not HOMA-IR was significantly lower in carriers of the PCSK9 46L variant compared with carriers of the wild-type allele . Panel (C) shows pancreatic islet size (*P < 0.001), while panels (D and E) show minor and major axis of each islet analysed (*P < 0.001 and *P < 0.001, respectively). In (F), islet size distribution, as percentage of total islets analysed, is shown. Islets were categorized according to the surface area (seven categories: from <10 000 lm 2 to >60 000 lm 2 ). Data shown in panels (C-F) were obtained from the analysis of 24 sections and 100 fields for each pancreas (mean ± standard deviation, n = 7 per group). 
(see Supplementary material online, Figure S4A and B) indicating that under PCSK9-deficient conditions, impaired b-cell functionality occurs also in humans.
These data suggest a relationship between PCSK9 deficiency and insulin secretion and prompted us to investigate the molecular mechanisms responsible for this effect.
PCSK9 effect on glucose metabolism is dependent on the presence of the lowdensity lipoprotein receptor
The LDLR is abundantly expressed also on the surface of pancreatic b cells where it plays a key role in the uptake of LDL.
9,10 Increased beta-cell cholesterol levels were associated with decreased insulin secretion. [22] [23] [24] The analysis of pancreatic sections from WT and Pcsk9 KO mice showed that LDLR is present mainly in b cells ( Figure 4A and Supplementary material online, Figure S5A ), and as detected by western blot analysis ( Figure 4B and C) and FACS analysis ( Figure 4D and Supplementary material online, Figure S5B ), its expression is increased in pancreatic islets isolated from Pcsk9 KO animals compared with WT mice. We next explored whether the increase in LDLR expression might be reflected in changes in pancreatic islets lipid content. Indeed, Pcsk9 KO mice islets presented higher cholesterol esters levels compared with WT islets, together with significant changes in fatty acid lipidome ( Figure 4E ). This lipid profile was paralleled by the down-regulation of genes involved in cholesterol biosynthesis and uptake, including HMGCoA-R and LDLR, the increase of the expression of ACAT1, which promotes cholesterol esterification ( Figure 4F ) and a non-significant increase in genes involved in cholesterol efflux ( Figure 4F ) and ABCA-1 protein expression (data not shown). Moreover, a similar expression of Annexin V, a marker of apoptosis, was observed in b cells from both animal models (see Supplementary material online, Figure S5C ) suggesting that, in vivo and at the time point analysed, cholesterol accumulation induces b-cell dysfunction before inducing cellular toxicity.
As expected, 25 plasma cholesterol levels were decreased in Pcsk9
KO mice compared with WT with most of the cholesterol transported on HDL (see Supplementary material online, Figure S6A and B).
To further test the hypothesis that the observed phenotype in Pcsk9 KO mice could be dependent on the impact on LDLR, GTT and ITT were evaluated in Pcsk9/Ldlr DKO mice and Ldlr KO animals. The delayed glucose response observed in Pcsk9-deficient conditions was not observed in SFD-fed Pcsk9/Ldlr DKO mice, and, indeed, GTT and ITT curves were superimposable between the two animal groups ( Figure 5A and B) and similar to those observed in WT animals. Also, fast and refeeding experiments resulted in similar plasma glucose levels (190 ± 15 mg/dL for Pcsk9/Ldlr DKO compared with 191 ± 16 mg/ dL for Ldlr KO mice).
Moreover, DKO mice and Ldlr KO littermates were characterized by similar levels of both plasma and pancreatic insulin levels (5.27 ± 2.78 ng/mL vs. 4 .67 ± 3 ng/mL, P = 0.666) (71.5 ± 64 ng/mg of tissue vs. 77.7 ± 56.6 ng/mg of tissue, P = 0.531) ( Figure 5C and D) . Pancreatic islets morphology was similar in both animal groups compared with WT ( Figure 5E and F) as was pancreatic islets cholesterol esters content (see Supplementary material online, Figure S7A ), indicating that the PCSK9/LDLR axis could explain the phenotype observed in Pcsk9-deficient animals.
Circulating PCSK9 does not impact glucose metabolism and beta-cell function
In humans, PCSK9 is mostly produced by the liver but is also synthesized to a relevant amount in the brain, the intestine, the lung, and the pancreas ( Figure 6A) . Pancreatic islets analysis in WT mice showed, in line with previous findings, 26 that PCSK9 is expressed in d cells but is under the level of detection in a or b cells ( Figure 6B and Supplementary material online, Figure S7B ). To dissect out the role of circulating, liver-derived PCSK9 9 from that of locally produced protein, we tested glucose metabolism in SFD-fed liver-specific Pcsk9 KO mice. PCSK9 protein was not detectable in plasma from AlbCreþ/ Pcsk9LoxP/LoxP, while in AlbCre-/Pcsk9LoxP/LoxP mice, plasma PCSK9 levels were 10.2 ± 4.2 mg/dL. PCSK9 mRNA expression was almost abolished in the liver from AlbCreþ/Pcsk9LoxP/LoxP, while mRNA and protein expression in pancreas were similar between AlbCreþ/Pcsk9LoxP/LoxP and AlbCre-/Pcsk9LoxP/LoxP mice ( Figure  6C and D), confirming the liver specificity of the KO model. Furthermore, plasma cholesterol levels in AlbCreþ/Pcsk9LoxP/LoxP mice were significantly lower compared with AlbCre-/Pcsk9LoxP/ LoxP (41.8 ± 7.6 mg/dL vs. 68.5 ± 10.1 mg/dL, P = 0.013) and similar to those observed in Pcsk9 KO mice (51.1 ± 14.0 mg/dL), further confirming the key role of liver derived, circulating PCSK9 on plasma cholesterol levels. The LDLR expression ( Figure 6E , and Supplementary material online, Figure S8A ) was similar in pancreatic islets from AlbCreþ/Pcsk9LoxP/LoxP and AlbCre-/Pcsk9LoxP/LoxP mice as were lipid levels in pancreatic islets (see Supplementary material online, Figure S8B ). AlbCre-/Pcsk9LoxP/LoxP mice presented similar GTT and ITT curves ( Figure 6F and G), and the same was true for plasma glucose levels following fast and refeeding experiments (194 ± 8 mg/dL for AlbCreþ/Pcsk9LoxP/LoxP mice compared with 192 ± 5 mg/dL for AlbCre-/Pcsk9LoxP/LoxP mice). Also pancreatic insulin levels were similar in the two animal models (133.6 ± 47.16 ng/ mg of tissue vs. 119.1 ± 43.2 ng/mg of tissue for AlbCreþ/Pcsk9LoxP/ LoxP and AlbCre-/Pcsk9LoxP/LoxP mice; P = 0.629). These data suggest that circulating, liver-derived PCSK9 does not impact LDLR expression in pancreas.
Discussion
Mendelian randomization studies have recently shown that PCSK9 genetic variants associated with lower LDL cholesterol are also associated with circulating higher fasting glucose concentration and an increased risk of Type 2 diabetes. [17] [18] [19] Here, we describe in experimental models, a possible mechanism beyond this causal association and identify LDLR in the pancreatic islets as the potential target of locally produced PCSK9.
The accumulation of cholesterol in pancreatic islets has been associated with reduced glucose induced insulin secretion 13 and cellular toxicity [22] [23] [24] pointing to the critical role of cholesterol metabolism in pancreas. Cholesterol influx in b cells mainly results from LDL uptake through the LDLR, 14 the latter is largely expressed in these cells. 17 In line with this, FH subjects bearing a loss of function mutation in the LDLR present a decreased risk of diabetes. 20 Also, pharmacological treatments resulting in increased LDLR expression, such as statins, increase the risk of diabetes, 27 thus indicating that excessive LDLR activity could be the driver of b-cell dysfunction and diabetes. On these premises and given the great interest in anti-PCSK9 therapies, we investigated in detail how PCSK9 deficiency could affect glucose metabolism. We show here that Pcsk9 KO mice present with impaired glucose tolerance, independent of the type of diet used (high fat or standard fat) but no insulin resistance. Previous findings on Pcsk9 KO are contrasting with a work reporting altered glucose metabolism following oral glucose tolerance test in Pcsk9 KO mice compared to littermates 15 and another reporting no difference between WT and Pcsk9
KO following intraperitoneal GTT. 26 Here, we take these observations forward by showing that Pcsk9 KO present decreased plasma insulin and C-peptide levels, a finding paralleled by altered pancreatic morphology and cholesterol esters accumulation, larger islets, and increased insulin content. The increase in cholesterol esters might mirror the intracellular response aimed at mitigating free cholesterol cell toxicity which might result in the long term in b-cell apoptosis. [22] [23] [24] This molecular adaptation might occur together with cellular reprogramming to increase cholesterol efflux. Of note, under hypercholesterolaemic conditions, selective b-cell ABCA-1 deficiency favours cholesterol accumulation in b cells, which associates to impaired insulin secretion. 28 The LDLR plays a key role in determining b-cell dysfunction under hypercholesterolaemic conditions 29 and Ldlr KO mice transplanted with WT islets with functional LDL present a normal functionality, 29 suggesting that compensatory mechanisms can maintain islet cholesterol homeostasis in this setting. These observations suggest that both cholesterol uptake and efflux are critical in maintaining a proper b-cell functionality.
It is important to stress that mice transport cholesterol mainly through HDL and that Pcsk9 KO mice present a significant reduction in cholesterol distribution in HDL 25 coupled with decreased levels of apoE-containing HDL and reduced efflux capacity. 30 It is, therefore, possible that also a decrease in HDL might contribute to cholesterol accumulation in b cells. Furthermore, the differences in lipids and lipoproteins metabolism in mice (based mainly on ApoA-I and ApoE containing liproproteins) compared with humans (based mainly on ApoB containing lipoproteins) suggest the need to further address the crosstalk among these pathways. Pcsk9 KO presented glucose intolerance when they were fed with either an SFD or an HFD; to limit the implications of insulin resistance driven by HFD, we performed most of the experiments on mice fed with an SFD. This does not exclude the possibility that on a longer time point, the development of metabolic abnormalities, as a consequence of HDF feeding, might mask part of the differences observed.
The presence of impaired b-cell function in Pcsk9 KO mice was further confirmed in humans, where subjects with a PCSK9 LOF variant presented decreased HOMA-BC but not HOMA-IR compared with age and sex matched carriers of the common allele.
The study of glucose metabolism in Pcsk9/Ldlr DKO mice showed that it is the PCSK9-LDLR axis and not the other known targets of PCSK9 such as the very low-density lipoprotein receptor, the apolipoprotein E receptor 2 (ApoER2), or cluster of differentiation 36 (CD36) [31] [32] [33] [34] to be responsible for the phenotype observed in Pcsk9 KO mice. This observation is critical given that anti-PCSK9 therapies have been recently approved for the treatment of FH and patients at very high cardiovascular risk. It is possible that, while on the one hand anti-PCSK9 therapies will reduce LDL-C levels and related mortality, on the other hand they increase the risk of diabetes. Data available so far with anti-PCSK9 therapies (up to 2.2 years of treatment) do not show an increased incidence of diabetes compared with the group under standard therapy, 35, 36 although a recent meta-analysis showed a significant increase in plasma glycaemia and glycated haemoglobin in patients treated with PCSK9 inhibitors that, however, was not sufficient to increase the incidence of diabetes. 37 Whether this effect might appear after longer term treatments remains to be addressed. Our data in PCSK9 tissue selective knock-out mice suggest an alternative explanation. Liver-selective Pcsk9 KO mice have PCSK9 plasma levels below the detection limit while maintaining PCSK9 production in other tissues including the pancreas. This setting closely mimics the conditions of patients treated with anti-PCSK9 antibodies where PCSK9 is absent the circulation, but it is still produced in extrahepatic tissues, in contrast to the genetic studies with PCSK9 LOF where all tissues present with a PCSK9-deficient condition. Liver-selective Pcsk9 KO mice present plasma and pancreatic insulin levels, LDLR expression as well as pancreatic islets cholesterol esters levels similar to those of control mice; accordingly, also glucose tolerance and insulin tolerance did not differ. These data indicate that circulating PCSK9 has a minimal if any effect on LDLR in pancreas and suggest the possibility that anti-PCSK9 therapies which target circulating PCSK9 might have a limited impact on LDLR expression in pancreas. Whether this is true also for gene-silencing approaches remains to be addressed. In summary, PCSK9 critically controls LDLR expression in pancreas perhaps contributing to the maintenance of a proper physiological balance to limit cholesterol overload in b cells. Pcsk9 deficiency in turn results in increased LDLR expression and cholesterol esters accumulation in pancreatic islets, which impairs insulin secretion (Take home figure) . Future studies should aim at addressing in humans the long-term safety of targeting circulating PCSK9 on pancreatic b-cell function.
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